[Diagnosis of haemoptoe/haemoptysis].

Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07

[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54

Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23

Clinical evaluation of a Mycobacterium tuberculosis PCR assay. J Clin Microbiol (1995) 2.19

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J (1996) 2.18

Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest (1998) 1.95

Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80

Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J (1995) 1.52

Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. Am Rev Respir Dis (1992) 1.49

Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46

[Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance]. Dtsch Med Wochenschr (2008) 1.45

Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J Clin Virol (2004) 1.39

Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39

Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J (2006) 1.29

Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28

Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J (2006) 1.28

Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis (2000) 1.27

[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26

Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J (2003) 1.24

Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24

Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19

Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis (1992) 1.17

Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol (1983) 1.08

Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07

Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med (1997) 1.05

Amplification of Mycobacterium tuberculosis from peripheral blood. J Clin Microbiol (1995) 1.03

Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03

Toxicity of quinolones. Drugs (1999) 1.03

Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02

Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis (1996) 1.01

Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00

Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00

Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99

Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr (1979) 0.99

Lymphocyte subsets in peripheral blood and smoking habits. Lung (1997) 0.98

Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother (1980) 0.98

Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother (1988) 0.97

Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J (1995) 0.97

Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem (1986) 0.97

Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. Eur Respir J (2004) 0.96

Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. J Chromatogr (1992) 0.96

Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents (1999) 0.96

Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci (1994) 0.96

Meropenem: clinical response in relation to in vitro susceptibility. Clin Microbiol Infect (2000) 0.96

Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis (1976) 0.94

Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med (2004) 0.93

Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents (2001) 0.92

Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother (1994) 0.92

HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis (2005) 0.91

Fluoroquinolones: interaction profile during enteral absorption. Drugs (1993) 0.91

Significance of non-pneumophila Legionella species in adult community-acquired and nosocomial pneumonias. Klin Wochenschr (1987) 0.91

Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine (2005) 0.90

Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. Infection (2006) 0.89

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother (1997) 0.88

[Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)]. Arzneimittelforschung (1980) 0.88

Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. Crit Care (2001) 0.88

Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection (2000) 0.87

Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J (1992) 0.87

Determination of trovafloxacin in human body fluids by high-performance liquid chromatography. J Chromatogr A (1999) 0.87

Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother (1990) 0.87

Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs (1988) 0.87

Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit (1987) 0.87

Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J (1997) 0.86

Pneumococcal vaccination. Eur Respir J (2005) 0.86

Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet (1985) 0.86

Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis (1993) 0.86

[A Q fever epidemic in Berlin. The epidemiological and clinical aspects]. Dtsch Med Wochenschr (1993) 0.86

Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother (1990) 0.86

Comparative clinical pharmacology of three ampicillins and amoxicillin administered orally. J Infect Dis (1974) 0.86

[Diagnosis and antibiotic treatment of infectious diseases in general practice. Results of an inquiry]. Dtsch Med Wochenschr (1983) 0.86

[Combination therapy using penicillin. Methods of analysis and pharmacokinetics of oxacillin and ampicillin administered simultaneously]. Arzneimittelforschung (1973) 0.85

Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother (1993) 0.85

Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells. Am Rev Respir Dis (1993) 0.85

Penetration of antibiotics into the pleural fluid. J Antimicrob Chemother (1979) 0.83

Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Eur J Med Res (1999) 0.83

Significance of pleural and sputum concentrations for antibiotic therapy of bronchopulmonary infections. Infection (1980) 0.83

Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy (1985) 0.83

[Septicemia. Etiology, epidemiology, clinical aspects and prognosis in 446 patients]. Dtsch Med Wochenschr (1983) 0.82

Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis (2005) 0.82

[Pharmacokinetic comparative studies on the resorption of 3 new cephalosporins]. Verh Dtsch Ges Inn Med (1978) 0.82

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother (2004) 0.82

Antibiotic infection prophylaxis in gallbladder surgery--a prospective randomized study. Chemotherapy (1985) 0.81

Combination therapy with beta-lactam antibiotics. J Antimicrob Chemother (1983) 0.81

Subpopulations of alveolar macrophages in smokers and nonsmokers: relation to the expression of CD11/CD18 molecules and superoxide anion production. Am J Respir Crit Care Med (1995) 0.81

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother (1996) 0.81

Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob Agents Chemother (2000) 0.81

[Inactivation of antibiotics in infusion solutions]. Infection (1973) 0.81

Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy (1984) 0.81

Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis (1995) 0.81

Supplementary dose after hemodialysis. Nephron (1982) 0.81

Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. Antimicrob Agents Chemother (1982) 0.81

[Changes in pulmonary function of young adults as a result of long time cigarette smoking]. Dtsch Med Wochenschr (1971) 0.81

Endothelin increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar macrophages. Am J Physiol (1991) 0.81

[Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy]. Med Monatsschr Pharm (2002) 0.81

Pharmacokinetics of temocillin in volunteers. Drugs (1985) 0.81

Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection (2008) 0.80

[Infectious endocarditis: clinical findings, therapy and course in 103 patients]. Dtsch Med Wochenschr (1982) 0.80